Header cover image

U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential

UPDATED Oct 01, 2022

Stocks with plenty of capacity to fund future growth

9 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
INCYIncyteUS$66.64-0.4%-2.3%US$14.8bUS$88.47PE15.7xE28.6%n/a
HZNPHorizon TherapeuticsUS$61.89-1.7%-43.7%US$14.3bUS$105.64PE18.6xE25.6%n/a
NBIXNeurocrine BiosciencesUS$106.212.6%4.7%US$10.2bUS$116.17PE832.6xE40.0%n/a
EXELExelixisUS$15.68-3.7%-27.2%US$5.0bUS$26.85PE18.5xE23.0%n/a
CORTCorcept TherapeuticsUS$25.642.2%29.2%US$2.7bUS$32.50PE24.4xE29.7%n/a
RCUSArcus BiosciencesUS$26.163.8%-25.7%US$1.9bUS$50.10PE28.3xE26.7%n/a
XOMAXOMAUS$17.915.4%-26.6%US$205.1mUS$62.50PE21.5xE65.3%n/a
CSBRChampions OncologyUS$7.50-5.1%-24.7%US$101.4mUS$15.33PE253xE93.1%n/a
LPCNLipocineUS$0.45-9.4%-57.5%US$39.8mUS$3.33PE11.6xE41.8%n/a
Page 1 of 1